Pharma Business review is using cookies

ContinueLearn More
Close
October 22, 2018

Lynparza reduces disease progression risk in ovarian cancer study

A phase III trial has demonstrated that Lynparza maintenance therapy reduced risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer.

Image: AstraZeneca and Merck’s Lynparza has reduced risk of disease progression or death in ovarian cancer study. Photo: courtesy of AstraZeneca.